December 18, 2018 08:03 AM EST

Entrada launches today, taking a $59M shot at some tough intracellular targets

John Carroll

Editor & Founder

Earlier this year, Ohio State singled out Professor Dehua Pei for the commercial promise he’d demonstrated for his work, praising his work involving the discovery …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Entrada launches today, taking a $59M shot at some tough intracellular targets

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

En­tra­da launch­es to­day, tak­ing a $59M shot at some tough in­tra­cel­lu­lar tar­gets

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Entrada launches today, taking a $59M shot at some tough intracellular targets

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway